Objective Study on Tongue Diagnosis of Chronic Atrophic Gastritis (NCT06489132) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Objective Study on Tongue Diagnosis of Chronic Atrophic Gastritis
498 participantsStarted 2024-07
Plain-language summary
Chronic atrophic gastritis with intestinal metaplasia or dysplasia is called precancerous lesions of gastric cancer ( PLGC ). It is an important stage in the transformation of normal mucosa to gastric cancer and is significantly associated with the risk of gastric cancer. Early identification of PLGC high-risk groups is the focus of prevention and treatment of gastric cancer. Gastroscopy and pathological examination are the key means to diagnose PLGC. However, due to the invasiveness, high cost, strong professional operability and traumatic pathological sampling, the application of gastroscopy is greatly limited, and the predictive significance of serum markers for the occurrence and prognosis of PLGC is limited. The current PLGC monitoring methods are not targeted enough, and there is still a lack of effective risk prediction models for PLGC. New screening methods are needed to improve the early diagnosis rate of PLGC. Tongue diagnosis is simple, convenient, easy and inexpensive. It can dynamically monitor the risk of PLGC in patients with chronic atrophic gastritis in early real time, and timely formulate individualized intervention measures, which is of great significance for improving the prognosis of patients, controlling medical expenses and truncating disease progression. Based on the objectification of tongue diagnosis, it may become an important method for screening PLGC from the perspective of macroscopic tongue image characteristics and microscopic tongue coating flora.
Who can participate
Age range
40 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
( 1 ) Upper gastrointestinal endoscopy was performed within 3 months ; ( 2 ) Patients with chronic atrophic gastritis diagnosed by gastroscopy and pathological examination ; ( 3 ) Age 40-70 years old, gender unlimited ; ( 4 ) agreed to collect tongue image and accept follow-up ; ( 5 ) Volunteered to participate in this study and signed informed consent.
Exclusion Criteria:
( 1 ) those who cannot cooperate with standardized tongue image collection and data collection ; ( 2 ) patients with tongue scraping, tongue coating or abnormal tongue extension ; ( 3 ) Suspected gastric malignant tendency or gastric tumor and history of gastric surgery ; ( 4 ) Have hepatitis, syphilis, HIV, schistosomiasis and other known infectious diseases ; ( 5 ) patients with severe heart, liver, kidney, blood diseases and malignant tumors ; ( 6 ) Combined with acute respiratory tract infection, active peptic ulcer and other acute diseases ; ( 7 ) Patients who used antibiotics, acid inhibitors and microecological regulators within 1 month ; ( 8 ) long-term use of immunosuppressive agents, hormones and other drugs ; ( 9 ) pregnant or lactating women.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation between tongue image characteristics and PLGC
Timeframe: two years
2
Construction of PLGC risk prediction model based on tongue image features